EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC0

Effects of MDMA-assisted therapy for PTSD on self-experience

Bessel A van der Kolk iD, Julie B Wang iD, Rachel Yehuda, Leah Bedrosian, Allison R Coker iD, Charlotte Harrison, Michael Mithoefer iD, Berra Yazar-Klosinki iD, Amy Emerson, Rick Doblin

PLOS ONE · 10.01.2024 · 19 (1) · e0295926

DOI: 10.1371/journal.pone.0295926 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, online erschienen am 10.01.2024. Verfasst von Bessel A van der Kolk und 9 weiteren Autor:innen. Beteiligte Einrichtung: Trauma Research Foundation, Brookline, MA, United States of America. Hauptthemen laut MEDLINE: N-Methyl-3,4-methylenedioxyamphetamine, Stress Disorders, Post-Traumatic, Hallucinogens. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Multidisciplinary Association for Psychedlic Studies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

There is a resurgence of interest in the therapeutic potential of psychedelic substances such as 3,4-methylenedioxymethamphetamine (MDMA). Primary findings from our randomized, double-blind, placebo-controlled, multi-site Phase 3 clinical trial of participants with severe PTSD (NCT03537014) showed that MDMA-assisted therapy induced significant attenuation in the Clinician-Administered PTSD Scale for DSM-5 compared to Therapy with placebo. Deficits in emotional coping skills and altered self-capacities constitute major obstacles to successful completion of available treatments. The current analysis evaluated the differential effects of MDMA-assisted therapy and Therapy with placebo on 3 transdiagnostic outcome measures and explored the contribution of changes in self-experience to improvement in PTSD scores.

Methods

Participants were randomized to receive manualized therapy with either MDMA or placebo during 3 experimental sessions in combination with 3 preparation and 9 integration therapy visits. Symptoms were measured at baseline and 2 months after the last experimental session using the 20-item Toronto Alexithymia Scale (TAS-20), the 26-item Self Compassion Scale (SCS), and the 63-item Inventory of Altered Self-Capacities (IASC).

Results

90 participants were randomized and dosed (MDMA-assisted therapy, n = 46; Therapy with placebo, n = 44); 84.4% (76/90) had histories of developmental trauma, and 87.8% (79/90) had suffered multiple traumas. MDMA-assisted therapy facilitated statistically significant greater improvement on the TAS-20, the SCS, and most IASC factors of interpersonal conflicts; idealization disillusionment; abandonment concerns; identity impairment; self-awareness; susceptibility to influence; affect dysregulation; affect instability; affect skill deficit; tension reduction activities; the only exception was identity diffusion.

Conclusion

Compared with Therapy with placebo, MDMA-assisted therapy had significant positive effects on transdiagnostic mental processes of self-experience which are often associated with poor treatment outcome. This provides a possible window into understanding the psychological capacities facilitated by psychedelic agents that may result in significant improvements in PTSD symptomatology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

N-Methyl-3,4-methylenedioxyamphetamineStress Disorders, Post-TraumaticHallucinogensHumansAnxietyCoping Skills

Substanzen

N-Methyl-3,4-methylenedioxyamphetamineHallucinogens

Autor:innen und Institutionen

  • Trauma Research Foundation, Brookline, MA, United States of America.
  • MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, United States of America.
  • James J. Peters Veterans Affairs Medical Center, Bronx, NY, United States of America.
  • Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.
  • University of California, San Francisco, San Francisco, CA, United States of America.
  • Multidisciplinary Association for Psychedelic Studies (MAPS), San Jose, CA, United States of America.

ORCID-Profile: Bessel A van der Kolk, Julie B Wang, Allison R Coker, Michael Mithoefer, Berra Yazar-Klosinki

Förderung

  • Multidisciplinary Association for Psychedlic Studies

Zitieren

APA

van der Kolk, B. A., Wang, J. B., Yehuda, R., Bedrosian, L., Coker, A. R., Harrison, C., Mithoefer, M., Yazar-Klosinki, B., Emerson, A., & Doblin, R. (2024). Effects of MDMA-assisted therapy for PTSD on self-experience. PLOS ONE, 19(1), e0295926. https://doi.org/10.1371/journal.pone.0295926

Vancouver

van der Kolk BA, Wang JB, Yehuda R, Bedrosian L, Coker AR, Harrison C, et al. Effects of MDMA-assisted therapy for PTSD on self-experience. PLOS ONE. 2024;19(1):e0295926. doi:10.1371/journal.pone.0295926

BibTeX
@article{vanderKolk2024,
  author = {van der Kolk, Bessel A and Wang, Julie B and Yehuda, Rachel and Bedrosian, Leah and Coker, Allison R and Harrison, Charlotte and Mithoefer, Michael and Yazar-Klosinki, Berra and Emerson, Amy and Doblin, Rick},
  title = {Effects of MDMA-assisted therapy for PTSD on self-experience},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {1},
  pages = {e0295926},
  doi = {10.1371/journal.pone.0295926}
}
Kostenlos starten →